Clinical Trial Update: Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab as prophylaxis to prevent chronic graft-versus-host disease after allogeneic stem cell transplantation; the study is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Mast Cell Leukemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Stanford University | Conditions: Leukemia, Mast-Cell, Mantle-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-28